Notizie AIOM – anno XVI n. 663

20 Febbraio 2018

New ACCC Report Focuses on Immuno-Oncology, Cancer Care Delivery

February 16, 2018 - As innovations in immunotherapies multiply, cancer programs and practices must overcome care coordination and communication challenges across the nation’s health-care system to integrate these advances into effective patient care. A new report from ...
Leggi tutto

20 Febbraio 2018

FDA expands approval of Durvalumab to reduce the risk of non-small cell lung cancer progressing

February 16, 2018 - The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed ...
Leggi tutto

20 Febbraio 2018

ASCO and NCCN Provide Guidelines for Managing Immunotherapy Side Effects

February 15, 2018 - Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body’s immune system to attack cancer, these treatments ...
Leggi tutto

20 Febbraio 2018

New International Practice Guidelines for Using CYP2D6 Genotype to Guide Antiestrogen Treatment in Breast Cancer

February 16, 2018 - An international group of clinicians and scientists representing the Clinical Pharmacogenetics Implementation Consortium (CPIC) published the first-ever clinical practice guidelines for using CYP2D6 genotype to guide tamoxifen therapy. Their research ...
Leggi tutto

20 Febbraio 2018

ASCO Endorses CAP/IASLC/AMP Guideline Update on Molecular Testing for Targeted Tyrosine Kinase Inhibitor Treatment in Lung Cancer

February 16, 2018 - As reported in the Journal of Clinical Oncology by Gregory P. Kalemkerian, MD, and colleagues, ASCO has endorsed the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular ...
Leggi tutto

20 Febbraio 2018

FDA Approves Durvalumab for Locally Advanced NSCLC

February 16, 2018 - The FDA has approved durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy. The approval is based on the phase III PACIFIC trial, ...
Leggi tutto

20 Febbraio 2018

Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial

We compared the efficacy and toxicity of neoadjuvant chemotherapy followed by radical surgery versus standard cisplatin-based chemoradiation in patients with locally advanced squamous cervical cancer. This was a single-center, phase III, randomized controlled trial ( ClinicalTrials.gov ...
Leggi tutto

16 Febbraio 2018

FDA Grants Priority Review to Ivosidenib for IDH1+ AML

February 15, 2018 - The FDA has granted a priority review designation to ivosidenib (AG-120) for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia (AML), according to a statement from Agios Pharmaceuticals, the company developing the targeted ...
Leggi tutto

16 Febbraio 2018

Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis

According to current ESMO - MASCC guidelines, a combination of a neurokinin-1 receptor antagonist (NK1RA), dexamethasone and a 5-HT3 receptor antagonist (5-HT3RA) is recommended to prevent carboplatin-induced emesis, albeit with moderate level of confidence and not unanimous ...
Leggi tutto

16 Febbraio 2018

Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab

Biomarkers to guide treatment in metastatic renal-cell carcinoma (mRCC) are lacking. We aimed to investigate the association between pretreatment neutrophil-to-lymphocyte ratio (NLR) and outcome of patients with mRCC receiving nivolumab. Through retrospective chart review, ...
Leggi tutto

LAVORIAMO CON

News

ICTUS, SCARSA QUALITÀ DELLA VITA NEL POST RIABILITAZIONE PER 1 PAZIENTE SU 4

SCOPERTE 74 REGIONI DNA LEGATE A METABOLISMO E CHILI DI TROPPO

BRISTOL MYERS SQUIBB OTTIENE L’APPROVAZIONE DELLA COMMISSIONE EUROPEA PER NIVOLUMAB NEL TRATTAMENTO ADIUVANTE DI PAZIENTI CON TUMORE ESOFAGEO O DELLA GIUNZIONE GASTRO-ESOFAGEA CON MALATTIA PATOLOGICA RESIDUA DOPO CHEMIO-RADIOTERAPIA

ACTO LOMBARDIA RINNOVA GLI APPUNTAMENTI CON “LA CASA DELLE DONNE”

ACTO PUGLIA PORTA “MOVIMENTO E SALUTE” IN REGIONE

CELGENE, ORA PARTE DI BRISTOL-MYERS SQUIBB, ANNUNCIA I RISULTATI PRELIMINARI DELLO STUDIO A LUNGO TERMINE CHE RAFFORZANO IL PROFILO DI EFFICACIA E SICUREZZA DI OZANIMOD NEI PAZIENTI CON FORME RECIDIVANTI DI SCLEROSI MULTIPLA

POLIAMBULANZA, 20 POSTI LETTO PER I PAZIENTI SUB ACUTI PRESSO LA RSA KORIAN “COSI’ PROVIAMO A SUPERARE I LIMITI IMPOSTI DALLA PANDEMIA”

Notizie AIOM – anno XVI n. 663

New ACCC Report Focuses on Immuno-Oncology, Cancer Care Delivery

FDA expands approval of Durvalumab to reduce the risk of non-small cell lung cancer progressing

ASCO and NCCN Provide Guidelines for Managing Immunotherapy Side Effects

New International Practice Guidelines for Using CYP2D6 Genotype to Guide Antiestrogen Treatment in Breast Cancer

ASCO Endorses CAP/IASLC/AMP Guideline Update on Molecular Testing for Targeted Tyrosine Kinase Inhibitor Treatment in Lung Cancer

FDA Approves Durvalumab for Locally Advanced NSCLC

Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial

FDA Grants Priority Review to Ivosidenib for IDH1+ AML

Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis

Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab